
CORRECTION



Wysong A, Newman JG, Covington KR, et al. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma. *J Am Acad Dermatol.* 2021;84(2):361-369.

For the above article, the authors have reported additional disclosures, as follows:

David Brodland reported the following relationships: Qual Perm Partners, shareholder, shares; P.E. shareholder, shares. Sarah Estrada reported the following relationships: Castle Bioscience, Inc., consultant honoraria, stockholder, stocks. Clare Johnson reported the following relationships: Castle Biosciences, Inc., employee, stock owner, stock options. Chrysalynne Schmults reported the following relationships: Castle Biosciences, Inc., steering committee member, honoraria; Regeneron Pharmaceuticals, steering committee member, consultant, honoraria; Sanofi, consultant, honoraria; received research funding from Castle Biosciences, Regeneron Pharmaceuticals, Novartis, Genentech, and Merck, and is a chair for NCCN; president of SCOUT. Lauren Meldi Sholl reported the following relationship: Castle Biosciences, Inc., employee, salary, and stock options. Darrell Rigel reported the following relationships: Castle Biosciences Advisory Board, speaker, honoraria; Castle Biosciences, Research Funding; Grants; GLG, Guidepoint Global, Gore Range, advisory services, honoraria/fees.